Indian IT and pharma stocks are not benefiting from a weaker rupee as expected. Tariff concerns are overshadowing currency gains. Investors are waiting for clarity on trade deals. Foreign investors have also been selling these stocks. Valuations remain a concern for pharma companies. Demand for IT services shows signs of improvement. Stock selection will be crucial for investors.
Kalyan Jewellers shares tumble 7% despite strong Q1 update. Details here
Kalyan Jewellers reported approximately 38% revenue growth in Q1 FY2027. This growth was driven by strong domestic and international business performance. The company’s gold recirculation